Page 29 - 南京医科大学自然版
P. 29

第46卷第5期           张志聪,戚晓瑜,马志芳,等. 两种测序技术在子宫内膜癌分子分型中的应用比较[J].
                  2026年5月                     南京医科大学学报(自然科学版),2026,46(5):644-651                         ·651 ·


                GU Yun was responsible for the provision of the research protocol  single molecule sequencing technology[J]. Guangxi Medi⁃
                and project funding support,guidance on the optimization of  cal Journal,2024,46(12):1935-1940
                research methods,and manuscript revision.        [10]卢美伊,朱志军,胡开明,等. 高通量测序技术在病原体
               [参考文献]                                                  检测中的临床应用进展[J]. 中国感染与化疗杂志,
                                                                       2023,23(1):107-110
               [1] BRAY F,LAVERSANNE M,SUNG H,et al. Global cancer
                                                                       LU M Y,ZHU Z J,HU K M,et al. Clinical application
                    statistics 2022:GLOBOCAN estimates of incidence and
                                                                       progress of high ⁃ throughput sequencing technology in
                    mortality worldwide for 36 cancers in 185 countries[J].
                                                                       pathogen detection[J]. Chinese Journal of Infection and
                    CA Cancer J Clin,2024,74(3):229-263
                                                                       Chemotherapy,2023,23(1):107-110
               [2] GALANT N,KRAWCZYK P,MONIST M,et al. Molecu⁃
                                                                 [11]MCALPINE J N,CHIU D S,NOUT R A,et al. Evaluation
                    lar classification of endometrial cancer and its impact on
                                                                       of treatment effects in patients with endometrial cancer
                    therapy selection[J]. Int J Mol Sci,2024,25(11):5893
                                                                       and POLE mutations:an individual patient data meta ⁃
               [3] 王家祎,郭瑞霞,姜国忠,等. 分子分型预测子宫内膜癌
                                                                       analysis[J]. Cancer,2021,127(14):2409-2422
                    及子宫内膜非典型增生患者保留生育功能治疗后的预
                                                                 [12]OAKNIN A,BOSSE T J,CREUTZBERG C L,et al. Endo⁃
                    后及生育结局[J]. 现代妇产科进展,2024,33(9):
                                                                       metrial cancer:ESMO Clinical Practice Guideline for
                    648-655
                                                                       diagnosis,treatment and follow⁃up[J]. Ann Oncol,2022,
                    WANG J Y,GUO R X,JIANG G Z,et al. Molecular
                                                                       33(9):860-877
                    typing predicts the prognosis and fertility outcomes of
                                                                 [13]OAKNIN A,GILBERT L,TINKER A V,et al. Safety and
                    patients with endometrial cancer and atypical endometrial
                                                                       antitumor activity of dostarlimab in patients with advanced
                    hyperplasia after fertility ⁃ sparing treatment[J]. Modern
                                                                       or recurrent DNA mismatch repair deficient/microsatellite
                    Advances in Obstetrics and Gynecology,2024,33(9):
                                                                       instability ⁃ high(dMMR/MSI ⁃ H) or proficient/stable
                    648-655
                                                                      (MMRp/MSS)endometrial cancer:interim results from
               [4] DORCA E,VELASCO A,VARELA M,et al. Validation
                                                                       GARNET⁃a phaseⅠ,single⁃arm study[J]. J Immunother
                    of Modaplex POLE mutation assay in endometrial carcino⁃
                                                                       Cancer,2022,10(1):e003777
                    ma[J]. Virchows Arch,2023,483(6):787-794
                                                                 [14]MENDIOLA M,HEREDIA⁃SOTO V,RUZ⁃CARACUEL
               [5] ZHU D Q,SHI K Y,HU D X,et al. Clinicopathological
                                                                       I,et al. Comparison of methods for testing mismatch
                    and molecular characterization of non ⁃ endometrioid
                                                                       repair status in endometrial cancer[J]. Int J Mol Sci,
                    endometrial carcinoma[J]. J Cancer,2025,16(7):2312-
                                                                       2023,24(19):14468
                    2320
               [6] 高    敏,宋    坤. 分子分型对子宫内膜癌诊治和预后                [15]RIEDINGER C J,ESNAKULA A,HAIGHT P J,et al.
                                                                       Characterization of mismatch ⁃ repair/microsatellite insta⁃
                    判断的临床价值及意义[J]. 实用妇产科杂志,2025,41
                                                                       bility⁃discordant endometrial cancers[J]. Cancer,2024,
                   (4):271-275
                                                                       130(3):385-399
                    GAO M,SONG K. Clinical value and significance of
                                                                 [16] LI Y,FENG J N,ZHAO C Z,et al. A new strategy in
                    molecular typing in the diagnosis,treatment and prognosis
                                                                       molecular typing:the accuracy of an NGS panel for the
                    of endometrial cancer[J]. Journal of Practical Obstetrics
                    and Gynecology,2025,41(4):271-275                  molecular classification of endometrial cancers[J]. Ann
               [7] KIM G,LEE S K,SUH D H,et al. Clinical evaluation of a  Transl Med,2022,10(16):870
                                                                 [17]SINGH N,PISKORZ A M,BOSSE T,et al. p53 immuno⁃
                    droplet digital PCR assay for detecting POLE mutations
                    and molecular classification of endometrial cancer[J]. J  histochemistry is an accurate surrogate for TP53 mutational
                                                                       analysis in endometrial carcinoma biopsies[J]. J Pathol,
                    Gynecol Oncol,2022,33(2):e15
               [8] ENNELI D. The importance of molecular classification in  2020,250(3):336-345
                    clinical practice of endometrial carcinomas:how to apply  [18] VERMIJ L,LÉON⁃CASTILLO A,SINGH N,et al. p53
                    it and difficulties in application[J]. J Turk Ger Gynecol  immunohistochemistry in endometrial cancer:clinical
                    Assoc,2023,24(3):197-205                           and molecular correlates in the PORTEC⁃3 trial[J]. Mod
               [9] 李红英,覃再隆. 单分子测序技术的应用与研究进展[J].                        Pathol,2022,35(10):1475-1483
                    广西医学,2024,46(12):1935-1940                     (收稿:2025-07-13;修回:2026-03-03;录用:2026-03-10)
                    LI H Y,QIN Z L. Application and research progress of                        (本文编辑:蒋      莉)
   24   25   26   27   28   29   30   31   32   33   34